The promise of bispecific antibodies: Clinical applications and challenges

Sun Min Lim, Kyoung Ho Pyo, Ross A. Soo, Byoung Chul Cho

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)


The development of cancer therapies using monoclonal antibodies has been successful during the last 30 years. Recently much progress was achieved with technologies involving bispecific and multi-specific antibodies. Bispecific antibodies (BsAbs) are antibodies that bind two distinct epitopes, and a large number of potential clinical applications of BsAbs have been described. Here we review mechanism of action, clinical development and future challenges of BsAbs which could be a serve as a valuable arsenal in cancer patients.

Original languageEnglish
Article number102240
JournalCancer Treatment Reviews
Publication statusPublished - 2021 Sep

Bibliographical note

Funding Information:
RAS- Advisory Board: Amgen, Astra-Zeneca, Bayer, BMS, Boehringer Ingelheim, Lilly, Merck, Novartis, Puma Biotechnology, Pfizer, Roche, Taiho, Takeda, Yuhan and research grants from Astra-Zeneca, Boehringer Ingelheim.

Publisher Copyright:
© 2021 Elsevier Ltd

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'The promise of bispecific antibodies: Clinical applications and challenges'. Together they form a unique fingerprint.

Cite this